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Context: Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is an 
autoimmune endocrinopathy with severe and unpredictable course. The impact of APECED on 
mortality has not been determined.
Objective: To assess overall and cause-specific mortality of patients with APECED.
Design and Setting: A follow-up study of Finnish patients with APECED from 1971 to 2018. 
Causes and dates of death were collected from Finnish registries.
Patients: Ninety-one patients with APECED.
Main Outcome Measure: Overall and cause-specific standardized mortality ratios (SMRs) 
determined by comparing the observed numbers of death and those expected on the basis of 
respective population death rates in Finland.
Results: The overall disease mortality was significantly increased (29 deaths, SMR 11; 95% confidence 
interval [CI] 7.2-16; P < 0.001). The relative risk (SMR) was highest in the youngest age groups but the 
absolute excess risk was similar (about 10 per 10 000 person-years) in all age categories. The highest 
SMRs were seen for endocrine and metabolic diseases (SMR 570; 95% CI, 270-1000; P < 0.001) and for 
oral and esophageal malignancies (SMR 170; 95% CI, 68-360; P < 0.001). Mortality was also increased 
for infections, diseases of digestive system, alcohol-related deaths, and for accidents. Due to the small 
number of cases we were unable to evaluate whether mortality was affected by disease severity.
Conclusions: Patients with APECED have significantly increased mortality in all age groups. 
Highest SMRs are found for causes that are directly related to APECED but also for infections. 
Increased alcohol- and accident-related deaths may be influenced by psychosocial factors. (J Clin 
Endocrinol Metab 105: e2207–e2213, 2020)
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Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED, OMIM 
#240300), also known as autoimmune polyendocrine 
syndrome 1 (APS-1) is a rare, monogenic autosomal 
recessive disease. It is caused by mutations in the 
Autoimmune Regulator (AIRE) gene located in chromo-
some 21q22.3 (1). AIRE participates in the regulation 
of self-tolerance of the developing T-cells in the thymus 
(2). Defective function of AIRE results in production of 
multiple anti-cytokine and organ-specific antibodies, 
and leads to a severe autoimmune disease affecting mul-
tiple endocrine organs and other tissues (3, 4).
More than 20 different clinical manifestations have 
been associated with the disease, and the highly variable 
presentation makes the course of the disease unpredict-
able. The first clinical manifestations are often diagnosed 
in the childhood and new manifestations may appear 
throughout the lifetime (5-10). The disease was classic-
ally diagnosed when 2 of the 3 most common mani-
festations, chronic mucocutaneous candidiasis (CMC), 
hypoparathyroidism (HP), and primary adrenal insuffi-
ciency (PAI), were present or when one of the common 
manifestations were present in an individual with a sib-
ling diagnosed with APECED (7). Today, APECED is 
often diagnosed by AIRE gene sequencing after initial 
manifestations, before the clinical criteria are fulfilled.
Only a few studies have described the mortality 
among patients with APECED by reporting the causes 
of death and age at death. In these studies, age at death 
varied from 3 to 64  years and median age at death 
from 5 to 34 years (10-14). According to the follow-up 
studies, the most common causes of death include 
hypocalcemia and adrenal crisis, oral and esophageal 
squamous cell carcinoma, and acute hepatitis (12-15). 
However, causes of death and mortality rates in com-
parison to the general population have not been system-
atically studied.
The Finnish APECED cohort is one of the largest 
worldwide, and the patients have been carefully fol-
lowed, mostly in tertiary centers, for decades. This 
unique setting gave us a possibility to carry out a system-
atic study on cause-specific mortality. We hypothesized 
that APECED-related causes would especially carry in-
creased mortality rates compared with the general popu-
lation. We also studied whether disease characteristics at 
an early stage of APECED would affect the mortality.
Methods
Patients and research permits
The Finnish cohort of patients with APECED formed the 
basis of the study (16, 17). The cohort was initially recruited 
from university and central hospitals by contacting the re-
spective endocrine and pediatric endocrine units. The cohort 
was later complemented by continuous recruitment of subse-
quently diagnosed patients from tertiary pediatric and adult 
endocrine centers throughout the country. The study was 
approved by the Research Ethics Committee of the Hospital 
District of Helsinki and Uusimaa. Informed written consent 
was obtained from all study participants or their guardians 
(for subjects aged < 18 years) at inclusion in the study.
Data collection for clinical manifestations and 
causes of death
Beginning of the follow-up was defined for each subject as 
the date when the patient for the first time was introduced to 
the Finnish APECED cohort, or the beginning of 1971, which-
ever was later. End of the follow-up was the date of death, 
emigration, or the end of 2018, whichever was first. We col-
lected the patient records from the hospitals in charge of the 
patients’ treatment and follow-up. From these patient records 
we extracted the age at diagnosis for the following disease 
manifestations: CMC, HP, PAI, diabetes, hypogonadism, 
hypothyroidism, growth hormone deficiency, hepatitis, intes-
tinal dysfunction, exocrine pancreatic insufficiency, nephritis, 
alopecia, vitiligo, keratopathy, enamel dysplasia, and rash 
with fever.
Out of all 93 patients in the APECED cohort, 2 subjects 
who were deceased before 1971 were excluded. Dates and 
causes of death were collected from the registry maintained 
by Statistics Finland or from the patients’ death certificates, 
using the Finnish personal identity codes as patient identifiers. 
Classification of cause of death is based on medical or forensic 
evidence, which provides grounds for death certification. 
Forensic determination is necessary if the patient died at home 
from an unknown cause, if death is not due to illness, if it is ac-
cidental or violent, or caused by a treatment procedure or oc-
cupational disease. Statistics Finland has combined a 54-group 
short list that categorizes causes of death (18). Causes of death 
were also collected as International Classification of Disease 
(ICD) codes to further specify the causes of death.
Standardized mortality ratio (SMR) calculations
For the statistical analysis, we counted overall and cause-
specific numbers of deaths observed in the cohort and person-
years at risk, by 5-year age groups, separately for males and 
females, and for eight 6-year calendar periods between 1971 
and 2018. We calculated the expected numbers of deaths by 
multiplying person-years in each stratum by the corresponding 
mortality rate in the population of Finland. Absolute excess 
risk (AER) in each age group was defined as ratio of excess 
number of deaths and person-years. To calculate SMRs for 
broader age ranges, we added up age-specific observed num-
bers of deaths and divided by the sum of expected numbers of 
respective age categories. The 54-group short list of causes of 
death by Statistics Finland was used in the SMR calculations.
For additional stratifications, we used the number of clin-
ical manifestations in the beginning of the follow-up (≤ 3 
or > 3 components). We also divided the patients into groups 
depending on whether they had HP and/or PAI in the begin-
ning of follow-up. To calculate 95% confidence intervals (CIs) 
for the SMRs, we assumed that the number of observed deaths 
followed a Poisson distribution.
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article/105/6/e2207/5809346 by guest on 07 Septem
ber 2020
doi:10.1210/clinem/dgaa140 https://academic.oup.com/jcem  e2209
Results
Patient characteristics
Altogether 46 female and 45 male Finnish patients 
with APECED were included in the present nation-
wide study (Table 1). This study population is likely to 
comprise the vast majority of the Finnish patients with 
APECED. The patients’ mean age at the beginning of 
follow-up was 12.3  years (median 10.5  years; range, 
0.7-42.7) and mean follow-up time 27.1 years (median 
27.0 years; range, 0.6-48.5). All patients were younger 
than 75 years at the end of the follow-up period.
Thirty-two of the 91 patients (35%) had more than 3 
clinical manifestations in the beginning of the follow-up 
period. Altogether, 67 (74%) patients had HP. PAI was 
present in 47 (52%), and 31 (34%) also had HP at the 
beginning of the follow-up period (Table 1). Eight (9%) 
patients did not have either HP or PAI in the beginning 
of the follow-up.
Of the included 91 patients, 29 (32% females) had 
died during 1971-2018. Altogether, 25 deaths were due to 
diseases and 4 due to accidents. The median age at death 
for all patients was 35.0 years (range, 11.0-62.8 years). 
The median age at death was 36.7 years (range, 11.0-
62.8  years) for patients deceased of disease-related 
causes and 18.1 years (range, 13.4-43.9) for patients de-
ceased of accidents. Altogether 21 patients (72%) had 
died before 45 years of age. The median age at death for 
females was 34.6 years (range, 13.0-56.9 years) and for 
males 35.9 years (range, 11.0-62.8 years).
Overall mortality
The SMRs for diseases and accidents were both about 
10-fold increased (Table 2). The SMRs for overall mor-
tality were significantly elevated and the absolute excess 
risks were 7- to 14-fold in all age groups (Table 2). The 
cumulative mortality rate up to age 60 exceeded 80% 
Table 1. Number of Patients (n) in the Study, by Age, Number of APECED Manifestations and 
Hypoparathyroidism (HP) and/or Primary Adrenal Insufficiency (PAI) Status at the Beginning of Follow-Up. 
Person-Years Given by Dynamic Age at Follow-Up, 1971-2018
Category
Female Male Total
n Person-years n Person-years n Person-years
Total 46 1301 45 1159 91 2458
Age, years       
 0-14 37 206 35 197 72 403
 15-29 9 493 6 468 15 961
 30-44 - 390 4 331 4 720
 45-59 - 198 - 141 - 339
 60-74 - 14 - 22 - 35
≤ 3 manifestations  32 939 27 670 59 1609
> 3 manifestations  14 361 18 459 32 820
HP+ PAI-  23 656 13 372 36 1028
HP- PAI+  - - 16 426 16 426
HP+ PAI+  21 597 10 208 31 805
HP- PAI-  2 46 6 152 8 198
Table 2. Observed (Obs) and Expected (Exp) Number of Deaths and Standardized Mortality Ratios (SMRs) 
With 95% Confidence Intervals (CIs) for All Causes, All Diseases and Accidents in the Whole Cohort and in 
Different Age Groups of Patients With APECED. For All-Cause Mortality, Also Shown Absolute Excess risks 
(AER) Per 1000 Person-Years
All diseases  Accidents  All causes 
Age at 
follow-up
Obs Exp SMR 95% CI Obs Exp SMR 95% CI Obs Exp SMR 95% CI AER
0-14 2 0.06 33 4.0-120 ** 1 0.04 25 0.63-140 3 0.10 30 6.2-87 *** 7.2
15-29 5 0.19 26 8.4-61 *** 2 0.47 4.2 0.51-15 7 0.67 10 4.2-22 *** 6.6
30-44 10 0.54 18 8.9-34 *** 1 0.39 2.6 0.06-14 11 0.94 12 5.9-21 *** 14
45-59 5 1.07 4.7 1.5-11 ** - 0.23 0.0 0.0-16 5 1.30 3.8 1.3-9.0 * 11
60-74 3 0.39 7.7 1.6-22 * - 0.03 0.0 0.0-120 3 0.43 7.1 1.5-21 * 7.3
Total 25 2.25 11 7.2-16 *** 4 0.56 7.2 2.0-18 * 29 3.43 8.5 5.7-12 *** 10
* P < 0.05; ** P < 0.01; *** P < 0.001.
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in patients with APECED while the respective rate in the 
general population was less than 10% (Fig. 1).
The SMR for all causes including accidents was 8.5 
(95% CI, 5.7-12; P < 0.001). The SMR for all diseases 
was 11 (95% CI, 7.2-16; P < 0.001) and for accidents, 
7.2 (95% CI, 2.0-18; P < 0.05). No deaths due to sui-
cide were reported. The accidents were classified as ac-
cidental fall, water transport accident, and accidental 
poisoning (non-alcohol).
The highest relative increase in the mortality was 
found in the youngest age groups < 45  years of age 
(Table 2). Significantly increased SMRs were found in 
all age groups for overall mortality and for disease-
related mortality.
Disease-specific mortality
The cause-specific SMRs, by gender, are reported 
in Table  3. SMRs for endocrine and metabolic dis-
eases other than diabetes (570; 95% CI, 270-1000) 
and for oral and esophageal malignancies (170; 95% 
CI, 68-360) were significantly increased (Table 3). No 
deaths due to diabetes were reported. SMRs for infec-
tions (36; 95% CI, 6.4-110, one death in each gender) 
and for diseases of digestive system (37; 95% CI, 4.5-
130; 2 deaths in males) were increased. According to 
ICD-classification, 1 death in the category of diseases of 
digestive system was due to hepatitis and the other due 
to inguinal hernia, which led to aspiration after surgery. 
Due to imprecise estimates, we were unable to evaluate 
whether mortality due to circulatory system and neuro-
logical diseases was different in the APECED cohort 
than in the general population. The SMR for alcohol-
related deaths was significantly increased (8.0; 95% CI, 
1.7-23).
There were no significant differences in SMRs for all 
diseases, endocrine and metabolic diseases, and oral and 
esophageal malignancies between subgroups stratified 
by the number and spectrum of manifestations at the 
beginning of follow-up (Table 4).
Discussion
This prospective cohort study reports the first systematic 
analysis of mortality and causes of death in APECED. In 
this study of 91 patients with APECED, we show that 
both the overall mortality and mortality for several 
disease-related causes were significantly increased. We 
also found a significant increase in the mortality from 
infections, alcohol-related causes, and accidents. We 
found the highest relative increase in the mortality in 
children and young adults, and most of the deaths oc-
curred before the age of 45 years.
The majority of the causes of patient deaths seem 
to be related to APECED. We found the highest mor-
tality rates and the highest number of deaths in endo-
crine diseases in both female and male patients. This 
finding is congruent with the previous studies that 
have reported several deaths due to endocrine causes, 
such as hypocalcemic and adrenal crisis (7, 12, 14). 
Mortality due to oral and esophageal malignancies was 
also strongly increased. Previous studies have shown 
increased risk of oral malignancies in patients with 
APECED. Altered T-cell function and oral candidiasis 
are reported to be probable factors increasing the risk 
for squamous cell carcinomas (15, 19). We also found 
increased mortality due to diseases of digestive system, 
based on deaths in male patients with APECED. One 
patient in this category had died of hepatitis, which has 
also previously been reported as a cause of death in 
APECED (7, 12, 14). Our findings confirm observations 
in earlier case series, reporting high number of deaths 
due to disease-related causes.
Importantly, our data also indicate for the first time, 
increased mortality due to infections in patients with 
APECED. There are few previous studies describing pa-
tients with severe infections and reporting deaths due to 
infections such as bacterial septicemias of various spe-
cies, pneumonia, measles, and influenza A  (7, 12, 14, 
20-22). It has been hypothesized that anticytokine auto-
antibodies, found in most of the patients, and asplenia 
may play a role in predisposing to severe infections 
(23, 24). However, increased mortality due to infec-
tions has not been reported before. Our observation has 
0.0
0.2
0.4
0.6
0.8
1.0
0 15 30 45 60
Age (years)
APECED
Populaon
Figure 1. Cumulative all-cause mortality in the cohort of patients 
with APECED and in the Finnish general population with similar 
sex and follow-up period distribution. The cumulative values are 
calculated based on mortality rates for 15-year age groups.
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significant clinical implications and warrants further 
research.
Mortality from alcohol-related deaths and acci-
dents was also increased in patients compared with the 
general population. The reason for increased risk of 
fatal accidents is not clear. The 54 categories of causes 
of death include suicides as a distinct category but no 
suicides were reported. As the patients have a high risk 
of alcohol-related deaths, increased mortality appears 
to be affected by social and mental factors in addition 
to the clinical disease. In addition to the clinical disease 
manifestations, psychosocial factors also strongly affect 
mortality since many patients suffer from depression 
and hopelessness (9).
Our study shows that mortality in patients with 
APECED was increased already at an early age and 
was similarly increased in all age groups. Due to small 
number of cases we were unable to evaluate whether 
mortality was affected by disease severity. In previous 
studies, PAI has been associated with increased mor-
tality attributed to malignancies, cardiovascular dis-
eases, and infections (26, 27). On the contrary, no clear 
Table 3. Observed (Obs) and Expected (Exp) Number of Deaths and Standardized Mortality Ratios (SMRs) 
With 95% Confidence Intervals (CIs) in Different Categories of Causes of Death Among Finnish Patients With 
APECED
Female Male Total
Cause of  
death
Obs Exp SMR 95% CI Obs Exp SMR 95% CI Obs Exp SMR 95% CI
All diseases 9 0.78 12 5.3-22 *** 16 1.48 11 6.2-18 *** 25 2.25 11 7.2-16 ***
Endocrine and 
metabolic 
diseases1
4 0.01 480 130-1200 *** 6 0.01 650 240-1400 *** 10 0.02 570 270-1000 ***
Malignant 
neoplasms
1 0.35 2.9 0.07-16 4 0.38 11 2.9-27 ** 5 0.73 6.9 2.2-16 **
Oral and 
esophageal 
malignancy
1 0.01 140 7.1-650 * 4 0.02 180 63-420 *** 5 0.03 170 69-360***
Diseases of 
digestive 
system
- 0.02 0.0 0.0-190 2 0.03 58 7.0-210 ** 2 0.05 37 4.5-130 **
Infectious 
diseases2
1 0.02 52 2.7-250 * 1 0.04 27 1.4-130 * 2 0.06 36 6.4-110 **
Diseases of  
the 
circulatory 
system
- 0.13 0.0 0.0-28 2 0.52 3.8 0.46-14 2 0.65 3.1 0.37-11
Neurological 
diseases
1 0.04 24 0.61-130 - 0.05 0.0 0.0-69 1 0.09 11 0.27-59
All alcohol 
related 
deaths
2 0.10 20 2.5-73 * 1 0.28 3.6 0.09-20 3 0.38 8.0 1.7-23 *
Accidents3 1 0.12 8.2 0.21-46 3 0.44 6.9 1.4-20 * 4 0.56 7.2 2.0-18 *
* P < 0.05; ** P < 0.01; *** P < 0.001; 1 Diabetes excluded; 2 HIV and tuberculosis excluded; 3 Alcohol related accidents excluded.
Table 4. Observed (Obs) and Expected (Exp) Number of Deaths and Standardized Mortality Ratios (SMRs) 
with 95% Confidence Intervals (CIs) for All Diseases and to Most Common Causes of Death. Patients are 
Divided in Subgroups Depending on Characteristics of the Disease in the Beginning of Follow-Up
All diseases
Endocrine and metabolic  
diseases
Oral and esophageal  
malignancy
Subgroup Obs Exp SMR 95% CI Obs Exp SMR 95% CI Obs Exp SMR 95% CI
≤3 manifestations 13 1.42 9.2 4.9-16 *** 4 0.01 340 93-870 *** 3 0.02 160 44-420 ***
>3 manifestations 12 0.83 14 7.4-25 *** 6 0.01 1000 380-2200 *** 2 0.01 190 34-590 ***
HP + PAI- 8 0.79 10 4.4-20 *** 4 0.01 540 150-1400 *** 1 0.01 100 5.3-490 *
HP- PAI+ 5 0.76 6.6 2.1-15 ** - 0.00 0.0 0.0-1000 2 0.02 170 30-520 ***
HP + and PAI+ 11 0.55 20 10-36 *** 5 0.00 1000 320-2300 *** 2 0.01 360 64-1100 ***
HP- and PAI- 1 0.15 6.8 0.17-38 1 0.00 640 16-3600 ** - 0.00 0.0 0.0-1700
Abbreviations: HP, hypoparathyroidism; PAI, primary adrenal insufficiency. * P < 0.05; ** P < 0.01; *** P < 0.001. 
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increase in mortality has been found in patients with 
hypoparathyroidism (28).
The low number of patients limits the power of the 
analyses. The cohort consisted of 91 patients, out of 
whom 29 had died by the end of 2018. Still, the Finnish 
cohort is one of the largest cohorts of patients with 
APECED, with a long follow-up. Thanks to the unique 
personal identity codes given to all residents in Finland 
since 1967 and the complete population registration 
system, the record linkages are accurate and there are 
no losses to follow-up (29). Even though there are po-
tential sources of errors in the process of registering 
causes of death, according to validation surveys, the 
Finnish causes of death have been found appropriate to 
serve as reference data in SMR statistics (30). Because 
the observed and expected deaths are based on the same 
registry, possible inaccuracies in coding are not likely to 
affect SMR estimates.
In conclusion, our study shows that overall mortality 
and mortality from APECED-related causes at all ages 
are significantly increased compared with the Finnish 
population. These findings are in accordance with 
previous studies that have reported deaths due to the 
clinical manifestations of the disease. In addition, our 
results suggest increased mortality due to previously un-
reported causes, such as infections. These results empha-
size the importance of careful monitoring of patients, 
with a special focus on endocrine manifestations, devel-
opment of oral neoplasms, infections, and psychosocial 
factors.
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